Analyst Price Targets — HRTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 9, 2025 10:08 am | Brandon Folkes | H.C. Wainwright | $6.00 | $2.12 | TheFly | Heron Therapeutics initiated with a Buy at H.C. Wainwright |
| May 16, 2024 2:04 pm | Carl Byrnes | Northland Securities | $9.00 | $3.22 | StreetInsider | Northland Reiterates Outperform Rating on Heron Therapeutics (HRTX) |
| March 13, 2024 7:08 am | Serge Belanger | Needham | $5.00 | $3.01 | StreetInsider | Heron Therapeutics (HRTX) PT Raised to $5 at Needham to reflect strong sales trends |
Latest News for HRTX
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Heron Therapeutics NASDAQ: HRTX reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while management said sales of its key products came in below its internal expectations.
CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.
BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HRTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.